NAMS — NEWAMSTERDAM PHARMA COMPANY

Ownership history in Frazier Life Sciences Management, L.P.  ·  13 quarters on record

AI Ownership Summary

Frazier Life Sciences Management, L.P. reported NEWAMSTERDAM PHARMA COMPANY (NAMS) in 13 quarterly 13F filings from 2023 Q3 through 2025 Q4. Peak portfolio weight reached 16.98% in 2024 Q4. The latest visible filing shows NAMS at 15.96% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this NAMS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Frazier Life Sciences Management, L.P.'s position in NEWAMSTERDAM PHARMA COMPANY, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

NAMS was reported at 15.96% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
16.98% in 2024 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q3 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

NAMS stock page Frazier Life Sciences Management, L.P. fund profile Frazier Life Sciences Management, L.P. full holdings
How Frazier Life Sciences Management, L.P. held NAMS — position size vs. price
% of Fund (quarterly)    NAMS price (quarter-end, indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 ADDED 16,943,774 +241,818 +1.4% 15.96% $594.4M 2026-02-14 (Est.) $34.63
2025 Q3 ADDED 16,701,956 +94,882 +0.6% 14.23% $475.0M 2025-11-14 $38.35
2025 Q2 ADDED 16,607,074 +490,656 +3.0% 12.03% $300.8M 2025-08-14 $25.17
2025 Q1 ADDED 16,116,418 +200,000 +1.3% 15.08% $329.9M 2025-05-15 $18.70
2024 Q4 ADDED 15,916,418 +3,061,224 +23.8% 16.98% $409.1M 2025-02-18 $20.04
2024 Q3 ADDED 12,855,194 +628,251 +5.1% 8.55% $213.4M 2024-11-15 $24.90
2024 Q2 UNCHANGED 12,226,943 — 0% 10.99% $234.9M 2024-08-15 $16.39
2024 Q1 ADDED 12,226,943 +95,238 +0.8% 12.20% $289.2M 2024-05-15 $19.81
2023 Q4 UNCHANGED 12,131,705 — 0% 7.25% $135.5M 2024-02-14 $20.05
2023 Q3 ADDED 12,131,705 +1,259,902 +11.6% 7.45% $112.2M 2023-11-14 $9.15
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding NAMS

As of 2025 Q4 — sorted by position size

FCPM III SERVICES B.V. 42.3% Bain Capital Life Sciences Investors, LLC 3Y 7Y 19.63% Medicxi Ventures Management (Jersey) Ltd 3Y 12.06% First Turn Management, LLC 3.58% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 3.43% Decheng Capital LLC 2.79% Artia Global Partners LP 3Y 2.5% Duquesne Family Office LLC 3Y 7Y 2.4% Atle Fund Management AB 3Y 7Y 2.21% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.87%

FAQ About Frazier Life Sciences Management, L.P. and NAMS

These are the practical questions this page is built to answer before you even open the full history table.

How long has Frazier Life Sciences Management, L.P. reported owning NAMS?

Frazier Life Sciences Management, L.P. reported NAMS across 10 quarterly 13F filings, from 2023 Q3 through 2025 Q4.

What was the largest reported NAMS position in Frazier Life Sciences Management, L.P.'s portfolio?

The largest reported portfolio weight for NAMS was 16.98% in 2024 Q4.

What is the latest reported NAMS position on this page?

The most recent filing on this page is 2025 Q4, when Frazier Life Sciences Management, L.P. reported 16,943,774 shares, equal to 15.96% of portfolio, with an estimated market value of $594.4M.

What does the chart on this NAMS ownership page compare?

The chart compares Frazier Life Sciences Management, L.P.'s quarterly NAMS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Frazier Life Sciences Management, L.P. Holdings